We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LAMP Test Rapidly Detects Sexually Transmitted Chlamydia

By LabMedica International staff writers
Posted on 10 Jan 2019
Print article
Image: A High Pure PCR template preparation kit (Photo courtesy of Roche Diagnostics).
Image: A High Pure PCR template preparation kit (Photo courtesy of Roche Diagnostics).
Chlamydia trachomatis is the leading cause of sexually transmitted diseases (STDs) in females and males in both developed and developing countries, with more than 110 million cases annually. C. trachomatis resists antibiotic treatment and is a cofactor in HIV transmission and human cervical cancer.

For nucleic acid amplification tests, recently loop-mediated isothermal amplification (LAMP) has presented an attractive alternative to standard methods like polymerase chain reaction (PCR) due to its low price, ease of use, rapid results, and lack of requirement for an expensive thermal cycler and specialized kits for DNA extraction and purification.

Scientists at the Chulalongkorn University (Bangkok, Thailand) and their associates have developed a rapid, inexpensive, easy-to-interpret, sensitive and specific point-of-care (POC) C. trachomatis detection system, using a LAMP assay for target C. trachomatis DNA amplification, followed by gold nanoparticle probe (AuNP) for colorimetric C. trachomatis specific readout.

The team collected endocervical swab samples were randomly selected from a prospective study cohort of sexually transmitted disease (STD) prevalence in symptomatic and healthy (which may include non-symptomatic patients) Thai women aged 15 to 54 years in Bangkok and nearby areas. The samples were collected by clinicians during 2011 and 2012 from qualified volunteers. The sample size of 130 (96 symptomatic and 34 healthy) was computed based on a standard statistical formula.

A set of six primers was designed for LAMP to target eight distinct regions on the C. trachomatis ompA gene. To determine the optimal LAMP assay condition (incubation temperature and incubation time), the LAMP reaction was incubated at 59 °C to 65 °C for 30 to 60 minutes (without loop primers) and 10 to 35 minutes (with loop primers). A 25 μL LAMP reaction comprised DNA template, High Pure PCR Template Preparation Kit. Nanogold particles of 10 nm were appended to the probe to create the complementary AuNP-DNA probe specific for the C. trachomatis LAMP product.

Of the 130 clinical samples, the LAMP-AuNP sensitivity was 96% (23/24) and specificity 99% (105/106). This result is higher than the LAMP-GE. The percentages of assay accuracy for PCR-GE and LAMP-AuNP were equal (98%), whereas for LAMP-GE it was 96%. The AuNPs allow simple visualization of results and improve the LAMP specificity and sensitivity. The percentages of assay accuracy for the independent replicate detection were 100% for PCR-GE, 99% for LAMP-AuNP, and 98% for LAMP-GE. Verification from the UV-vis spectra supported the convenient colorimetric reading of the LAMP-AuNP assay.

The authors concluded that the C. trachomatis LAMP-AuNP detection is appropriate for local and resource-constrained settings. The assay directly uses clinical samples, obtains results in 32 to 47 minutes and the result is readable by the naked eye. The study was published on December 20, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Chulalongkorn University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.